Therapeutic uses of inhibitors of RTP801

1. A method of treating a subject suffering from an eye disease which comprises administering to the subject an RTP801 inhibitor and a VEGF inhibitor, so as to thereby treat the subject, wherein the RTP801 inhibitor is an antisense compound or an siRNA compound which inhibits expression of the RTP801 gene.

2. The method of claim 1 , wherein the RTP801 inhibitor is an siRNA compound which inhibits RTP801 expression.

3. The method of claim 2 , wherein the RTP801 siRNA compound comprises an antisense strand, the sequence of which comprises a sequence selected from the group consisting of:

5′AGCUGCAUCAGGUUGGCAC

(SEQ ID NO: 66);

5′UUCUAGAUGGAAGACCCAG

(SEQ ID NO: 74);

5′UUGAACAUCAAGUGUAUUC

(SEQ ID NO: 75);

5′AAAAAUAUUGCAUAGGUCU

(SEQ ID NO: 77);

5′UACUUGAACAUCAAGUGUA

(SEQ ID NO: 79);

and

5′AACUCAAUGAGCUUCCUGG

(SEQ ID NO: 91).

4. The method of claim 3 , wherein the sequence is

5′AGCUGCAUCAGGUUGGCAC

(SEQ ID NO: 66).

5. The method of claim 1 , wherein the VEGF inhibitor is an anti-VEGF antibody.

6. The method of claim 5 , wherein the anti-VEGF antibody is Ranibizumab.

7. The method of claim 1 , wherein the administering comprises intravitreal injection.

8. The method of claim 1 , wherein the eye disease is selected from the group consisting of choroidal neovascularization (CNV), wet AMD, dry AMD, glaucoma, diabetic retinopathy, diabetic macular edema, ocular histoplasmosis syndrome, angioid streaks, ruptures in Bruch's membrane, myopic degeneration, ocular tumors, retinal degenerative disease, and retinal vein occlusion (RVO).

9. The method of claim 8 , wherein the eye disease is diabetic macular edema.